Stock Analiz

Scynexis Inc. SCYX

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$3.21Market cap $32M
Open the interactive analysis →

Scynexis Inc. (SCYX) is a healthcare company listed in the US with a market value of about $32M. In the twelve months to September 30, 2026 it had revenue of $19M and net income of -$10M, a net margin of -53.5%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is track record (0/5).

Key numbers: a P/E of 1.2, a 5-year average ROIC of -259%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.

About Scynexis

Scynexis is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $12M in 2014 to $21M in 2025, growth of about 5.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 17% over three years (dilution for shareholders). It spends 108% of revenue on research and development.

Score: 1.6 / 5

Value2/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)1.2
Forward P/E—
P/FCF—
P/S1.7
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−60%

Growth and quality

Revenue growth (1 yr)450.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-409.1%
ROIC (5-yr avg.)-259.3%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$19M$21M$4M$140M$5M$13M$0$121000$257000$257000$257000
Net income-$10M-$9M-$21M$67M-$63M-$33M-$55M-$54M-$12M-$25M-$30M
Free cash flow—————-$55M-$49M-$38M-$29M-$25M-$29M
EPS (diluted)$2.69$-0.17$-0.44$1.39$-1.47$-1.25$-5.15$-9.58$-2.84$-9.37$-15.80
Net margin-53.5%-41.8%-568.3%47.8%-1233.7%-249.7%—-44388.4%-4851.4%-9751.0%-11668.9%
ROIC—-31.2%-50.8%95.6%-1239.7%-70.5%-185.5%-300.9%-39.2%-73.0%-56.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Scynexis’s P/E ratio?

About 1.2, based on the last twelve months of diluted earnings per share.

Is Scynexis stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Scynexis pay a dividend?

Not currently.

Is Scynexis a good stock to buy?

We do not give buy or sell advice. Scynexis scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.